Devazepide
SIGMA/D3821 - ≥98% (HPLC), powder
Synonym: (S)
CAS Number: 103420-77-5
Empirical Formula (Hill Notation): C25H20N4O2
Molecular Weight: 408.45
MDL Number: MFCD00864500
Linear Formula: C25H20N4O2
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to off-white |
| form | powder |
| InChI | 1S/C25H20N4O2/c1-29-21-14 |
| InChI key | NFHRQQKPEBFUJK-HSZRJFAPSA |
| originator | Merck & Co., Inc., Kenilworth, NJ, U.S. |
| Quality Level | 100 ![]() |
| SMILES string | CN1C(=O)[C@@H](NC(=O)c2cc |
| solubility | DMSO: >5 mg/mL |
| storage condition | desiccated |
| storage temp. | 2-8°C |
| Application: | Devazepide has been used as a cholecystokinin receptor 1 (CCK1R) antagonist in human embryonic kidney 293T cells and in human pancreatic slices. |
| Biochem/physiol Actions: | Devazepide is a CCK1 (CCK-A) receptor antagonist and a CCK8 antagonist. |
| Biochem/physiol Actions: | Devazepide is a CCK1 receptor antagonist. |
| Biochem/physiol Actions: | Devazepide is a cholecystokinin octapeptide (CCK1) (CCK-A) receptor antagonist. It inhibits CCK binding to peripheral-type receptor (CCK-A). Devazepide reverses the cholecystokinin octapeptide (CCK-8) based antagonism towards morphine. |
| Features and Benefits: | This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S. . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| General description: | Devazepide is derived from asperlicin by chemical modification and has the benzodiazepine backbone. |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol | GHS06 |
| Signal word | Danger |
| Hazard statements | H300 |
| Precautionary statements | P264 - P301 + P310 |
| Hazard Codes | T+ |
| Risk Statements | 28 |
| Safety Statements | 28-36/37-45 |
| RIDADR | UN 2811 6.1 / PGI |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |


